Effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study.
liver transplant
pharmacokinetics
safety
tacrolimus
treatment failure
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
14
07
2023
received:
24
04
2023
accepted:
13
08
2023
pubmed:
24
8
2023
medline:
24
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Data comparing long-term effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplantation are scarce. We compared the effectiveness, pharmacokinetic profile, and safety of LCPT (Envarsus) and PR-Tac (Advagraf) for up to 12 months post-transplant. Adult de novo liver transplant recipients who started IR-Tac (Prograf) and were converted to LCPT or PR-Tac 3-5 days post-transplant were included. Data from 163 patients were analyzed, 87 treated with LCPT and 76 with PR-Tac. The incidence of treatment failure was 30.5% in the LCPT group versus 23.0% in the PR-Tac group (p = .291). Biopsy-proven acute rejection (BPAR) was reported in 26.8% of patients in the LCPT group and 17.6% in the PR-Tac group (p = .166). Graft loss was experienced in one patient (1.2%) in the LCPT group and three patients (4.1%) in the PR-Tac group (p = .346). Death was registered in three patients (3.7%) in the LCPT group and three patients (4.1%) in the PR-Tac group (p > .999). Patients in the LCPT group showed 45.7% higher relative bioavailability (C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15105Subventions
Organisme : Chiesi España S.A.U
Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: where are we now and where are we going? Transplant Rev. 2017;31(1):10-17. doi:10.1016/j.trre.2016.10.006
Charlton M, Levitsky J, Aqel B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102(5):727-743. doi:10.1097/TP.0000000000002147
Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006(4):CD005161. doi:10.1002/14651858.CD005161.pub2
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623-653. doi:10.2165/00003088-200443100-00001
Provenzani A. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol. 2013;19(48):9156. doi:10.3748/wjg.v19.i48.9156
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: liver transplantation. J Hepatol. 2016;64(2):433-485. doi:10.1016/j.jhep.2015.10.006
Grinyó JM, Petruzzelli S. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. Expert Rev Clin Immunol. 2014;10(12):1567-1579. doi:10.1586/1744666X.2014.983903
Burra P, Germani G, Gnoato F, et al. Adherence in liver transplant recipients. Liver Transplant. 2011;17(7):760-770. doi:10.1002/lt.22294
Kuypers DRJ, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus oncE-Daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95(2):333-340. doi:10.1097/TP.0b013e3182725532
Sukkha S, Chindavijak B, Montakantikul P, Ingsathit A, Nosoongnoen W, Sumethkul V. Trough level from twice daily to once daily tacrolimus in early conversion kidney transplant recipients: a prospective study. Int J Clin Pharm. 2017;39(6):1298-1303. doi:10.1007/s11096-017-0549-9
Sańko-Resmer J, Boillot O, Wolf P, Thorburn D. Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. Transpl Int. 2012;25(3):283-293. doi:10.1111/j.1432-2277.2011.01412.x
Niioka T, Satoh S, Kagaya H, et al. Comparison of pharmacokinetics and pharmacogenetics of once-and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation. 2012;94(10):1013-1019. doi:10.1097/TP.0b013e31826bc400
Toblli JE, Di Gennaro F. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. PLoS ONE. 2015;10(4):1-13. doi:10.1371/journal.pone.0125528
Alloway RR, Eckhoff DE, Washburn WK, Teperman LW. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transplant. 2014;20(5):564-575. doi:10.1002/lt.23844
Willuweit K, Frey A, Hörster A, Saner F, Herzer K. Real-world administration of once-daily meltdose® prolonged-release tacrolimus (LCPT) allows for dose reduction of tacrolimus and stabilizes graft function following liver transplantation. J Clin Med. 2020;10(1):124. doi:10.3390/jcm10010124
Altieri M, Delaval G, Kimmoun E, Allaire M, Salamé E, Dumortier J. Conversion from once-daily prolonged-release tacrolimus to once-daily extended-release tacrolimus in stable liver transplant recipients. Exp Clin Transplant. 2018;16(3):321-325. doi:10.6002/ect.2016.0328
von Einsiedel J, Thölking G, Wilms C, et al. Conversion from standard-release tacrolimus to MeltDose® tacrolimus (LCPT) improves renal function after liver transplantation. J Clin Med. 2020;9(6):1654. doi:10.3390/jcm9061654
DuBay DA, Teperman L, Ueda K, et al. Pharmacokinetics of once-daily extended-release tacrolimus tablets versus twice-daily capsules in de novo liver transplant. Clin Pharmacol Drug Dev. 2019;8(8):995-1008. doi:10.1002/cpdd.657
Baccarani U, Velkoski J, Pravisani R, et al. MeltDose technology vs once-daily prolonged release tacrolimus in de novo liver transplant recipients. Transplant Proc. 2019;51(9):2971-2973. doi:10.1016/j.transproceed.2019.03.084
Herden U, Sterneck M, Buchholz BM, Achilles EG, Ott A, Fischer L. A single-center, open-label, randomized cross-over study to evaluate the pharmacokinetics and bioavailability of once-daily prolonged-release formulations of tacrolimus in de novo liver transplant recipients. Immunity, Inflamm Dis. 2021;9(4):1771-1780. doi:10.1002/iid3.537
Kamar N, Cassuto E, Piotti G, et al. Pharmacokinetics of prolonged-release once-daily formulations of tacrolimus in de novo kidney transplant recipients: a randomized, parallel-group, open-label, multicenter study. Adv Ther. 2019;36(2):462-477. doi:10.1007/s12325-018-0855-1
Fernandez Rivera C, Calvo Rodríguez M, Poveda JL, et al. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study. Clin Transplant. 2022;36(3):e14550. doi:10.1111/ctr.14550
Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25(3):658-663. doi:10.1002/hep.510250328
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461-470. doi:10.7326/0003-4819-130-6-199903160-00002
Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transplant. 2010;16(8):943-949. doi:10.1002/lt.22091
TruneČka P, Klempnauer J, Bechstein WO, et al. Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens-the DIAMOND study. Am J Transplant. 2015;15(7):1843-1854. doi:10.1111/ajt.13182
Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a prograf-based regimen in stable liver transplant recipients. Transplantation. 2007;83(12):1639-1642. doi:10.1097/01.tp.0000265445.09987.f1
Soliman T, Gyoeri G, Salat A, Mejzlík V, Berlakovich G. A multi-centre non-interventional study to assess the tolerability and effectiveness of extended-release tacrolimus (LCPT) in de novo liver transplant patients. J Clin Med. 2023;12(7):2537. doi:10.3390/jcm12072537
Huang B, Liu J, Li J, et al. Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation. J Am Pharm Assoc. 2019;59(6):816-823.e2. doi:10.1016/j.japh.2019.08.002
Lim TY, McPhail MJ, Shah A, et al. Sequential cohort analysis after liver transplantation shows de novo extended release tacrolimus is safe, efficacious, and minimizes renal dysfunction. Transplant Direct. 2020;6(2):e528. doi:10.1097/TXD.0000000000000970
Ojo AO, Held PJ, Port FK, et al. Chronic renal faiure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931-940. doi:10.1056/nejmoa021744
Supplements KI. KDIGO 2017 Clinical Practice Guideline Update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001
Rodríguez-Perálvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2012;12(10):2797-2814. doi:10.1111/j.1600-6143.2012.04140.x
Budde K, Bunnapradist S, Grinyo JM, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of phase III, double-blind, randomized trial. Am J Transplant. 2014;14(12):2796-2806. doi:10.1111/ajt.12955
Bunnapradist S, Ciechanowski K, West-Thielke P, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant. 2013;13(3):760-769. doi:10.1111/ajt.12035
Weiler N, Thrun I, Eberlin M, et al. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? Transplant Proc. 2013;45(6):2321-2325. doi:10.1016/j.transproceed.2013.03.039